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Abstract
Background: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or
panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes.
However, a percentage of patients do not respond to this treatment. In addition to mutations in the RAS genes,
mutations in other genes, such as BRAF, PI3KCA, or PTEN, could be involved in the resistance to anti-EGFR moAb
therapy.
Methods: In order to develop a comprehensive approach for the detection of mutations and to eventually identify
other genes responsible for resistance to anti-EGFR moAbs, we investigated a panel of 21 genes by parallel sequencing
on the Ion Torrent Personal Genome Machine platform. We sequenced 65 CRCs that were treated with cetuximab or
panitumumab. Among these, 37 samples were responsive and 28 were resistant.
Results: We confirmed that mutations in EGFR-pathway genes (KRAS, NRAS, BRAF, PI3KCA) were relevant for conferring
resistance to therapy and could predict response (p = 0.001). After exclusion of KRAS, NRAS, BRAF and PI3KCA combined
mutations could still significantly associate to resistant phenotype (p = 0.045, by Fisher exact test). In addition, mutations
in FBXW7 and SMAD4 were prevalent in cases that were non-responsive to anti-EGFR moAb. After we combined the
mutations of all genes (excluding KRAS), the ability to predict response to therapy improved significantly (p = 0.002, by
Fisher exact test).
Conclusions: The combination of mutations at KRAS and at the five gene panel demonstrates the usefulness and
feasibility of multigene sequencing to assess response to anti-EGFR moAbs. The application of parallel sequencing
technology in clinical practice, in addition to its innate ability to simultaneously examine the genetic status of several
cancer genes, proved to be more accurate and sensitive than the presently in use traditional approaches.
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Background
Colorectal cancer (CRC) is the third most frequent
neoplasm worldwide and the third most common cause
of cancer-related death in Western countries. CRC is
treated with surgical resection and/or systemic chemo-
therapy based on fluorouracil, irinotecan, oxaliplatin, or
capecitabine. Cetuximab and panitumumab, monoclonal
antibodies (moAbs) that target the epidermal growth fac-
tor receptor (EGFR), are also used in metastatic CRC.
However, only 10–20 % of patients affected by metastatic
CRC are responsive to this treatment [1].
EGFR protein promotes cell growth and survival signal-
ing through the activation of MAPK and PI3K pathways.
Mutation analysis of genes belonging to these pathways
revealed that alterations in KRAS, as well as in N- and
HRAS, represented biomarkers of the lack of response to
cetuximab [1, 2]. As a result, RAS mutation analysis was
introduced into clinical guidelines for the selection of
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patients amenable to cetuximab treatment. The focused
use of cetuximab against tumors harboring wild-type RAS
improved its overall usefulness. However, 35–45 % of
wild-type RAS cases still do not respond to this treatment.
Additional studies have now indicated that other elements
of the MAPK and PI3K pathways, such as BRAF, PI3KCA,
or PTEN, may be involved [1, 3–5]. These findings led to
updated guidelines for CRC treatments, which advocated
the inclusion of the mutational status of both KRAS and
NRAS genes and the consideration of BRAF mutations in
wild-type RAS cancers [6]. High-throughput sequencing
methods, thanks to their ability to analyze several genes in
parallel, could represent a helpful support in detecting the
numerous genetic changes implicated in anti-EGFR moAb
resistance.
With massive parallel sequencing, millions of fragments
of DNA can be sequenced in the same reaction, allowing
the acquisition of in-depth information that traditional
Sanger sequencing cannot readily achieve. For this reason,
the use of parallel sequencing technologies is rapidly
expanding. In addition to instruments that can sequence
full human genomes, “bench” sequencers with lower
throughput—but reduced running costs and faster turn-
around time—are becoming common. These bench se-
quencing systems are more apt when a relatively small
number of genes need to be sequenced. Sample prepar-
ation and data analysis are compatible with barcoding,
meaning that multiple samples can be labeled and loaded
in the same sequencing assay, allowing consistent time
and cost savings. For these reasons, in addition to simpler
data analysis, this type of sequencer can be more easily
accommodated in a clinical setting.
In this study, we selected a group of 21 genes involved
in CRC [1, 7] to sequence 65 CRCs from patients treated
with cetuximab or panitumumab by using the Ion Torrent
Personal Genome Machine (PGM) platform. The study
proved the usefulness of parallel sequencing, confirmed
earlier reports about the genes involved in cetuximab
resistance, and revealed a potential important role for
FBXW7 and SMAD4 mutations in conferring therapy
resistance to anti-EGFR moAbs.
Methods
Clinical samples
Samples were obtained from 65 patients with histologically
confirmed colorectal adenocarcinoma and undergoing sur-
gery at the Masaryk Memorial Cancer Institute (MMCI,
Brno, Czech Republic) between 2004 and 2011. Patient age
ranged from 31 to 81 years with a mean of 58 years.
The Ethical committee of the Masaryk Memorial Cancer
Institute approved the study protocol. Written informed
consent was obtained from all patients. All partici-
pants included in the study were anonymized by using
sample identifiers that could not be connected with
any individual. Clinicopathological features of the pa-
tients are summarized in Table 1 and Additional file 1:
Figure S1. At the time the samples were collected, the
TheraScreen K-RAS Mutation Kit CE-IVD was in use.
The test allowed analysis of the mutational status at
codons 12 and 13 of KRAS only. According to the results
of this test, all 65 samples carried wild-type KRAS, and pa-
tients were treated with cetuximab or panitumumab. At
the time of first diagnosis, tumors of some patients were
at stages I-III, but at the time of anti-EGFR moAb treat-
ment, all patients were at stage IV. Patients were regularly
followed up after beginning this treatment. End points
of follow-up were death and progression of disease.
Cetuximab response was assessed according to RECIST
(Response Evaluation Criteria In Solid Tumors) criteria.
Enrolled patients were divided into two groups: one group
(responders) included patients with a complete response
(CR; 100 % reduction of metastasis) or a partial response
(PR; >30 % reduction of metastasis) or with stabilization of
the disease (SD), whereas a second group (non-responders)
included patients with progressive disease (PD).
Table 1 Clinical features of colon cancer samples
Non-responders Responders




Age, years 58.3 57.9
Gender M 18 24
F 10 13
Localization R 6 1
L 21 34
ND 1 2









Treatment Cetuximab 23 29
Panitumumab 5 8
OS, average months 34.8 61.5
TTP, average months 3.6 14.9
PD progressive disease, CR complete response, PR partial response, SD stable
disease, M male, F female, R right colon, L left colon, OS overall survival,
TTP time to progression, ND not determine
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Gene selection and primer design
The CRC gene panel was assembled by considering the
19 most frequently mutated genes in non-hypermutated
CRCs [7]; to these, EGFR and BRAF genes were added
for their involvement in the EGFR pathway [1, 3–5]. Gene
regions and the 584 primer pairs are listed in Additional
file 2: Table S1. Primer pairs for the amplification of each
gene region of interest were designed by using AmpliSeq
Designer v.1.2.6 software [8] (Life Technologies).
Isolation of DNA and sample selection
DNA was isolated from formalin-fixed, paraffin-embedded
(FFPE) samples by using the QIAamp DNA FFPE Tissue
Kit (Qiagen) according to the manufacturer’s protocol. No
enrichment for tumor cells was done, however, according
to histopathological analysis, the average percentage of
tumor cells in tissue sections was 70 %. The concentration
of DNA was ascertained with the Qubit 2.0 Fluorometer
(Life Technologies) by using the Qubit dsDNA HS Assay
Kit (Life Technologies).
Library preparation and sequencing
Library preparation was performed according to the Ion
AmpliSeq Library Kit 2.0 protocol (Life Technologies),
starting with 20 ng of genomic DNA. Two 20-cycle
multiplex amplification reactions of the regions of interest
were performed by using AmpliSeq custom oligos. An Ion
Xpress Barcode Adapters Kit (Life Technologies) was used
to add Ion Torrent specific motifs to amplicons. For puri-
fication, an Agencourt AMPure XP reagent (Beckman
Coulter) was used. Final libraries were quantified by using
the Bioanalyzer instrument with the High Sensitivity DNA
Kit (Agilent), diluted and pooled together in equimolar
amounts. Twenty microliters of a 16 pM pool of all librar-
ies was mixed with Ion Sphere Particles and clonally amp-
lified in an emulsion PCR, performed in accordance with
the Ion OneTouch 200 Template kit v.2 DL protocol and
using the Ion OneTouch instrument (Life Technologies).
Enrichment-System and Dynabeads MyOne Streptavidin
C1 magnetic beads (Life Technologies) were used to
enrich template-positive Ion Sphere Particles. Enriched
samples were loaded onto Ion 316 (up to 8 samples) or
318 chips (up to 17 samples) and sequenced by using the
Ion Torrent PGM, following the Ion PGM 200 Sequencing
Kit protocol.
Data analysis and variant identification
Sequencing data analysis was conducted by using Torrent
Suite software v. 3.4 (Life Technologies). Briefly, low-quality
reads were removed, adapter sequences trimmed, and
alignment against a reference genome (hg19) performed
by using the Torrent Mapping Alignment Program. The
Variant Caller plugin was used to identify variations from
the reference sequence. To identify pathogenic variations,
mutations that did not affect the protein coding regions
(intronic, 3’ and 5’ UTR variations and silent exonic muta-
tions) were filtered out; insertions and deletions belonging
to homopolymeric regions were removed, because se-
quencing error rate is high in these regions; alterations
found at a frequency lower than 15 % were excluded, based
on the hypothesis that mutations at lower frequencies could
marginally affect tumor behavior and because this filtering
step allowed to remove most of variations derived from
formalin fixation artifacts [9]. Remaining mutations were
compared with data present in the public databases dbSNP
[10], COSMIC [11], and cBIO [12] to search for known
pathogenic mutations. Annotated non-pathogenic vari-
ations were excluded from results, whereas remaining
potentially pathogenic variations and mutations of un-
known significance were retained. At the same time,
Annovar [13] and Mutation Assessor [14] algorithms were
used to predict damaging or potentially damaging changes
in tumor suppressor genes.
Statistical analysis
The association of gene mutations with anti-EGFR treat-
ment resistance was evaluated by using a two-tailed Fisher’s
exact test. GraphPad Prism 5 was used to perform survival
analysis.
Sanger sequencing
Sanger sequencing was performed according to standard
procedure. Amplicons were prepared using the same
primer pairs employed for library preparation and were
sequenced using the following sequencing primers: CGT
CCA CAA AAT GAT TCT GAA TTA GC for amino acids
12 and 13 of KRAS; TGC ACT GTA ATA ATC CAG ACT
GTG TTT for amino acid 61 of KRAS; GGA TTA AGA
AGC AAT GCC CTC TCA for amino acid 146 of KRAS;
GAT TTT TGT GAATAC TGG GAA CTATG for amino
acids 600 and 616 of BRAF; TGT AGA TGT GGC TCG
CCA ATT AA for amino acid 12 of NRAS and TTG AAC
TTC CCT CCC TCC CT for amino acid 61 of NRAS; CCT
TGA CTA AAT CTA CCA TGT TTT CTC A for amino
acids 479, 481, and 505 of FBXW7; ATG CCT TCA TTT
TTC TCT TCA CCA GTA for amino acid 399 of FBXW7;
CGT GTG GTA GAG GAG GAA CAG for amino acid 81
of FBXW7; and GGT CAG TAA TTG ATA GGA AGA
GTATCC A for amino acid 582 of FBXW7.
Results
Detection of anti-EGFR treatment-related genes through
next-generation sequencing
The DNA of primary tumor lesions from 65 advanced
CRCs treated with cetuximab or panitumumab (Table 1,
Additional file 1: Figure S1) was investigated. Thirty-seven
patients were responsive to therapy, whereas 28 displayed
progression of disease. The two groups were balanced for
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age, sex, stage, and grade. A slight difference in tumor
localization was present, with a prevalence of right colon
cancers in the non-responder group (p = 0.04). All samples
were negative for KRAS mutations according to the Ther-
aScreen K-RAS Mutation Test.
We investigated the coding sequences of 21 genes, se-
lected according to the previously reported genes most
frequently mutated in CRCs [3, 5, 7] or present in public
cancer mutations databases, such as COSMIC [11] and
cBioPortal [12] (Additional file 2: Table S1). Amplicon
libraries and sequencing reactions were performed as
described in the Methods.
All designed gene segments (n = 584) were sequenced
with an average coverage of 506 reads each. Variations
were identified in comparison with a human nucleotide
reference sequence (hg19) by the Variant Caller plugin
(Torrent Suite v. 3.4). To identify potentially pathogenic
variations, we filtered out some identified nucleotide
changes, as indicated in the Materials and Methods. All
of the remaining variations are listed in Additional file 3:
Table S2.
At least one mutation was detected in each sample,
the only exception being sample ID_5032. This sample
showed a complete response to anti-EGFR treatment. The
most frequently mutated genes were TP53 and APC,
which were mutated in 40 (62 %) and 37 samples (57 %),
respectively. These results are in agreement with the pub-
lished literature, which, besides confirming the importance
of these two genes for CRC pathogenesis, validates the
reliability of our sequencing results. The mutation rate
for the remaining genes was as follows: 17 % for KRAS
(additional mutations, previously undetected by TheraSc-
reen test), 14 % for CSMD3, 14 % for TCF7L2, 9 % for
PIK3CA and FBXW7, and less for the other genes. No
mutation was detected in SMAD2 (Fig. 1).
Mutation rates for each gene in the responder and
non-responder groups are shown in Fig. 1. The two genes
with the highest mutation frequency, TP53 and APC,
displayed mutations in both groups: TP53 had a higher
mutation frequency in responders than in non-responders
(70 % versus 50 %), but the difference was not significant
(p = 0.125); APC showed a similar mutation frequency in
both responders and non-responders (59 % versus 54 %).
Despite initial analyses based on TheraScreen KRAS
Mutation Test indicating that all tumors carried a wild-type
KRAS gene, the subsequent next-generation sequencing
(NGS) analysis revealed that 11 primary tumors harbored a
mutation in this gene. In particular, we found the following
variations: G12C, G12V, G13D, Q61H, Q61L, and A146T.
All of these alterations were previously described as patho-
genic for the KRAS gene and recorded in the COSMIC
database. Eight of the 11 samples were found in patients
who were resistant to anti-EGFR treatment, whereas
the other three KRAS mutated samples belonged to the
responder group. Of these three responsive tumors,
one sample with a Q61H variation (detected in 54 % of
reads) was from a patient with stable disease, and two
samples harboring Q61H and G13D (detected in less than
18 % of reads) were from patients who showed a partial
response to treatment. These additional, previously un-
detected mutations in the KRAS gene alone were signifi-
cantly associated with the appearance of drug resistance
(p = 0.045) (Table 2 and Additional file 4: Table S3).
Besides KRAS, the mutational status of BRAF, NRAS,
and PIK3CA was already shown to correlate with cetuxi-
mab resistance. In this study, BRAF and PI3KCA genes
displayed an imbalance (>2 fold), albeit not a statistically
significant one, in mutations detected in the responder
patients as compared with those in the non-responder
patients (Table 2). We detected five BRAF mutations
(V600E and S616F), two NRAS (Q61R and G12D), and
six PIK3CA variations (R38H, I391M, and H1047L). All
of these variations were annotated in the COSMIC
database. Considering a combination of these three genes,
eight mutations belonged to tumors that did not respond
to therapy, and three mutations were in samples from pa-
tients that showed either a partial response or stable dis-
ease (Additional file 3: Table S2). Notably, mutations in
KRAS, BRAF, NRAS, and PIK3CA appeared to be mutually
exclusive (Fig. 1 and Additional file 1: Figure S2). Because
these four genes are downstream effectors of the EGFR-
induced pathways, they appear to be functionally signifi-
cant in driving cetuximab or panitumumab resistance.
Combined NRAS, BRAF and PIK3CA mutation frequency
significantly correlated to anti-EGFR resistance phenotype
(p = 0.045) (Table 2). If additional KRAS mutations, found
by NGS, were considered in addition to the three genes
of the panel, the combined mutation frequency became
highly significantly correlated with resistance to anti-EGFR
therapy (p = 0.001) (Additional file 4: Table S3).
To validate these findings, we confirmed the presence of
mutations in KRAS, BRAF, and NRAS genes by the stand-
ard Sanger sequencing method (Fig. 2 and Additional file 1:
Figure S3). From the chromatograms, we noticed that mu-
tant nucleotides were called by Sanger sequencing only in
the case of high-frequency mutations (e.g., KRAS G12C,
found in 63 % of reads of sample ID_5060), whereas in
the vast majority of samples, mutant nucleotides could
be observed by visual inspection of chromatograms,
but they were not called by the analysis software, as
wild-type nucleotides were prevalent. These results con-
firm the better qualitative and quantitative accuracy of
NGS data.
Besides genes of the EGFR pathway, the other genes
most frequently mutated in CRCs included CSMD3 (14 %),
TCF7L2 (14 %), and FBXW7 (9 %) (Fig. 1). Whereas
CSMD3 and TCF7L2 mutations were equally distrib-
uted between the two groups, mutations in FBXW7
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Fig. 1 Mutations in the 21-gene panel in tumor samples from patients who underwent anti-EGFR therapy. Black squares indicate the presence of
a mutation. The overall frequencies of gene mutations, as well as the frequencies in the responder and non-responder groups, are shown at the
bottom of the figure
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were prevalent (6.6-fold difference) in resistant samples, as
they were found in five resistant samples and in only
one responder belonging to the stable disease subgroup
(p = 0.077) (Table 2). The FBXW7 mutations included a
nucleotide insertion involving amino acid 481 (A481fs) in
15 % of reads; a nonsense mutation R479* (COSM206697)
in 57 % of reads; two missense variations (D399Y and
N81S) in 19 and 57 % of reads, respectively; the variation
R505C in 24 % of reads (COSM22975); and missense mu-
tation S582L (COSM22979) found in 21 % of reads. With
the exception of N81S, which is a variation of unknown
clinical significance annotated in the dbSNP database
(rs139738471), all of the other variations occur inside
WD-40 domains (also known as WD or beta-transducin
repeats) (Fig. 3), which are responsible for protein-protein
interactions. These five mutations are predicted to have
significant effects on protein stability, suggesting that they
interfere with the production of a functional FBXW7 pro-
tein. As mentioned earlier, the only responder sample with
a FBXW7 mutation (ID_5428 with mutation S582L in
21 % of reads) belonged to the stable disease group. If
samples from the borderline stable disease group are not
considered, the statistical association between FBXW7
mutations and resistance to cetuximab becomes signifi-
cant (p = 0.05). Moreover, if the FBXW7 mutations are
considered together with BRAF, NRAS, and PIK3CA alter-
ations, the significance of the association with the chemo-
response is further increased (p = 0.016) (Table 2). All of
the mutations in FBXW7 were further validated by Sanger
sequencing (Additional file 1: Figure S3). Mutations in
the SMAD4 gene also exhibited an imbalance (5.3-fold
change) between the non-responder and the responder
patients: four mutations were found in samples from
the non-responders and one mutation was found in a
patient with a partial response to anti-EGFR therapy
(Fig. 1 and Additional file 1: Figure S2). As in all of the
other individual genes, with the exception of KRAS, the
difference was not statistically significant (p = 0.16) (Table 2).
However, if all of the genes with imbalanced mutations
(excluding KRAS) are considered in responders versus
non-responders, 13 cases (46 %) exhibit a mutation in
at least one of the five genes (NRAS, BRAF, PI3KCA,
FBXW7, and SMAD4) among the non-responders and
4 (11 %) among the responders. This difference is sta-
tistically highly significant (p = 0.002) (Table 2). If the
additional KRAS variations are included within the five
gene panels, significance strikingly improves (p = 0.0001)
(Additional file 4: Table S3).
Discussion
Anti-EGFR therapy based on cetuximab or panitumumab
moAbs is administered to treat advanced CRCs that carry
a wild-type KRAS gene [1, 3–5]. Nonetheless, some pa-
tients do not respond to this therapy, as genes other than
KRAS are involved in the resistance to anti-EGFR mole-
cules. Indeed, previous work has reported the involvement
of mutations in genes such as BRAF, PIK3CA, and PTEN
[1, 3–5]. All of these genes represent down-stream effec-
tors or modulators of the EGFR pathway, thus establishing
a rationale for the anti-EGFR moAb response. More re-
cently, new guidelines for the use of cetuximab and
panitumumab treatment in CRC patients supported the
analysis of the mutational status of both KRAS and
NRAS genes and BRAF in wild-type RAS cancers [6].
Samples analyzed in this study were antecedent to these
guidelines and were evaluated only for the mutational
status of KRAS (codons 12 and 13).
Here, we performed a targeted resequencing of a group
of genes previously reported as the most frequently mu-
tated genes in non-hypermutated CRCs [7]: TP53, APC,
KRAS, CSMD3,TCF7L2, PI3KCA, FBXW7, SOX9, SMAD4,
PTPRD, GPC6, EDNRB, GNAS, AMER1, NRAS, KIAA1804,
Table 2 Correlation between mutational status and resistance to anti-EGFR moAb therapy
Mutant genes Responders (CR + PR + SD)a vs non-responders
Total responders Total non-responders Mutant responders Mutant non-responders P-valueb
KRASc 37 28 3 8 0.045
NRAS 37 28 1 1 0.999
BRAF 37 28 1 4 0.156
PI3KCA 37 28 2 4 0.389
FBXW7 37 28 1 5 0.077
SMAD4 37 28 1 4 0.156
NRAS/BRAF/PIK3CAd 37 28 3 8 0.045
NRAS/BRAF/PIK3CA/FBXW7d 37 28 4 11 0.016
NRAS/BRAF/PIK3CA/FBXW7/SMAD4d 37 28 4 13 0.002
aCR complete response, PR partial response, SD stable disease
bP-value from Fisher's exact test
cPreviously undetected mutations
dSamples with mutations in at least one of the indicated genes
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Fig. 2 Sanger sequencing validation of some KRAS mutations. All 11 KRAS mutations identified by NGS were also validated by using Sanger
sequencing. The figure shows a comparison between NGS and Sanger sequencing results for four KRAS mutations. On the left are displayed
Sanger chromatograms, while results of NGS, showing read alignment to the reference genome, are on the right of the panel
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Fig. 3 Gene mutation diagram. Position of mutations found in KRAS, NRAS, BRAF, PIK3CA, FBXW7, and SMAD4 proteins. Red circles indicate the
position of mutations within protein domains, which are responsible for protein-protein interactions or enzymatic activities. RBD, Raf-like Ras-binding
domain; C1_1, phorbol esters/diacylglycerol binding domain (C1 domain); Pkinase_Tyr, protein tyrosine kinase; PI3K_p85B, PI3-kinase family,
p85-binding domain; PI3K_rbd, PI3-kinase family, ras-binding domain; PI3K_C2, phosphoinositide 3-kinase C2; PI3Ka, phosphoinositide 3-kinase
family, accessory domain (PIK domain); PI3_PI4_kinase, phosphatidylinositol 3- and 4-kinase; WD40, WD domain, G-beta repeat
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CTNNB1, ACVR1B, and SMAD2. Analysis of EGFR and
BRAF were added for their known involvement in the
EGFR signaling pathway. Using this 21-gene panel, we
investigated 65 CRC samples from patients treated with
anti-EGFR moAbs to uncover genes whose mutational
status could be associated with differential sensitivity
to therapy. This study proves the feasibility of high-
throughput sequencing of several genes in large num-
bers of samples to get detailed information about the
mutational status of analyzed genes and it highlights
the better sensitivity of NGS technologies compared
to traditional capillary sequencing.
The most frequently mutated genes in our samples
were TP53 and APC. Since these two genes have been
previously described as the most frequently mutated in
CRC [7, 15], this finding validates the reliability of our se-
quencing results. Although a higher percentage of mutant
TP53 was detected in responders, no significant correl-
ation between the mutational status of these two genes
and the resistance phenotype was found (p = 0.125).
We also found that a number of genes, including KRAS
(previously undetected mutations), BRAF, PI3KCA, FBXW7,
and SMAD4, exhibited a higher frequency (>2-fold) of
mutations in non-responders than in responders.
Notably, although the samples were classified as wild-
type KRAS by the TheraScreen KRAS Mutation Test, se-
quencing of primary lesions identified the presence of
additional mutations in the KRAS gene in 11 samples.
This discrepancy partially occurred because the Therasc-
reen test consists of an allele-specific PCR able to detect
seven mutations at codons 12 and 13 of the KRAS gene,
whereas codons 61 and 146, whose clinical significance
has now been proven, were not covered by the assay.
However, five of the KRAS mutations were at codons 12
and 13. A similar underestimation of KRAS mutated sam-
ples using this assay was previously found by Dono and
colleagues [16], and differences between NGS and routine
clinical assays have been previously described [17].
Surprisingly, mutations in KRAS were also discovered
in samples belonging to the responder group. Contrasting
significance had already been reported for the KRAS-G13D
mutation, found in sample ID_5443 [18]. Our results do
not help to clarify the issue, since another G13D mutation
was detected in a non-responsive patient (ID_5074). Con-
trasting data were also obtained for the Q61H mutation:
two cases were found within the responders (ID_5064 and
ID_5408) and one within the non-responders (ID_5454).
An additional different mutation at codon 61 (Q61L in
sample ID_5430) was found in non-responders. A Q61R
mutation was also found to affect NRAS in a non-
responder case (ID_5035). These findings suggest that a
complex picture emerges in deciphering the role of the
RAS mutation in conferring resistance to moAbs against
EGFR; in particular, the response of mutations at codons
13 or 61 may depend on the type of mutation and possibly
on other tumor alterations that may affect individual
susceptibility.
With the exception of NRAS, alterations in genes in-
volved in the EGFR pathway other than KRAS generally ex-
hibited an imbalance, albeit at lower frequencies, between
responder and non-responder patients. Overall, mutations
in NRAS were found in 3 % of samples, in BRAF in 8 %,
and in PIK3CA in 9 %. The detected mutation rates over-
lapped those reported by Smith and colleagues in a study
performed on a large series of CRCs [19]. Our data
confirmed that mutations in these genes were generally
mutually exclusive. The combined mutations in NRAS,
BRAF, and PIK3CA could predict resistance to anti-EGFR
moAbs with a statistically significant value, as recently also
highlighted by Ciardiello and colleagues [17]. The associ-
ation of mutations in these three genes with the resistant
phenotype had a p-value of 0.045. Although the newly
identified KRAS mutations alone significantly associated
with anti-EGFR resistant phenotype (p = 0.045), we ex-
cluded KRAS gene from correlation calculations because
patients’ cohort was initially selected for wt KRAS status,
thus potentially producing a bias in KRAS mutation fre-
quency. It should be highlighted that, if KRAS gene is
added to the panel, prediction significance will strikingly
increase (Additional file 4: Table S3)”.
Two other genes, the E3 ubiquitin protein ligase F-box
and WD repeat domain containing 7 (FBXW7 or FBW7)
and the SMAD family member 4 (SMAD4), exhibited an
imbalance in mutations between responders and non-
responders. Mutations in FBXW7 were identified in six
samples (9 %): five in the non-responders and one in the
stable disease subgroup of the responders. No FBXW7
mutation was detected in patients with a partial or a
complete response. FBXW7 mutations alone were associ-
ated with a resistant phenotype with a p-value of 0.077.
However, by adding FBXW7 to the NRAS-BRAF-PIK3CA
mutation panel, the significance of the panel became
stronger (p-value of 0.016). The involvement of FBXW7 in
resistance to traditional chemotherapies has been previ-
ously reported [20] (for a review, see [21]). Mutations
in FBXW7 in human CRCs were previously found in
11–12 % of cases [7, 15] and its low expression was shown
to be correlated with a poor prognosis [22]. Down-
regulation of FBXW7 expression was also reported in other
cancers [23, 24] and leukemias [25–27]. F-box proteins
constitute one of the subunits of the ubiquitin protein ligase
complex and they function in the ubiquitin-mediated deg-
radation of several cellular proteins. Genes belonging to the
ubiquitin proteasome complex are often mutated in cancer,
leading to reduced oncoprotein turnover [28]. In particular,
FBXW7 is the component for substrate recognition [21]
and, through its F-box domain, is able to bind and mediate
the degradation of some known oncogenes, including cyclin
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E [29], c-Myc [30], c-Jun [31], c-Myb [32], Notch [31], and
mTOR [33]. Since nearly all of the mutations we found in
FBXW7 affected the WD-40 domains, which are respon-
sible for protein-protein interactions, and they all appear to
be inactivating mutations that are able to interfere with
the production of a functional FBXW7 protein, the re-
sults of this work provide evidence for a potential role
of inactivating mutations in conferring resistance to
anti-EGFR moAbs. Importantly, previous mutational stud-
ies and animal models have shown that even monoallelic
mutations in FBXW7 could be sufficient to promote
tumorigenesis [34, 35], suggesting that these mutations
could dominantly affect functionality of the ubiquitin pro-
teasome complex. The mechanism through which muta-
tions in FBXW7 could impair cetuximab or panitumumab
efficacy requires further studies. It is possible that, since
some of its proven targets are downstream effectors of
EGFR, mutations of FBXW7 could impair their degrad-
ation and thus contribute to the resistant phenotype.
One other gene that appeared potentially interesting is
SMAD4. Like the mutations in FBXW7, mutations in
SMAD4 appear to be unbalanced, with one mutation in
a responder sample versus four mutations in resistant
samples. Although not significant in itself (p-value of 0.16)
in our sample cohort, combining mutations in SMAD4
with those in NRAS-BRAF-PIK3CA-FBXW7 further im-
proved the significance of the panel (p-value of 0.002).
Given the function of SMAD4 protein, a possible involve-
ment of a non-functional TGFβ pathway in conferring
resistance to anti-EGFR moAbs might be suggested.
Conclusions
By sequencing a panel of 21 genes involved in CRC, we
found that, beside KRAS gene, whose previously undetected
mutations reached statistical significance as individual gene,
the combined mutations of other genes belonging to
the EGFR pathway (NRAS, BRAF and PIK3CA) together
with mutations at FBXW7 and SMAD4 genes achieved a
significant association with resistance to anti-EGFR therapy.
These results indicate that mutations at KRAS combined
with the 5 gene panel found in this study, have a strong po-
tential for predicting response to anti-EGFR moAbs. This
work supports the usefulness of NGS technology and mul-
tigene sequencing over the traditional capillary sequencing
for improving patient management in a clinical setting.
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